Navigation Links
NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
Date:3/4/2009

Product Candidate NVC-422 Demonstrates Ability to Treat Subcutaneous Infections

EMERYVILLE, Calif., March 4 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE Alternext: NBY), a clinical stage biopharmaceutical company, today announced that new preclinical data related to NVC-422, the lead molecule in NovaBay's, proprietary Aganocide(R) class of compounds, will be presented at the American Academy of Dermatology (AAD) 67th Annual Meeting in San Francisco during March 6-10, 2009. NovaBay is focused on developing first-in-class, novel, synthetic anti-infective product candidates that are bioequivalent to the active antimicrobial molecules generated within white blood cells for the treatment and prevention of bacterial, fungal, and viral infections without developing resistance.

"We have new data at the upcoming AAD annual meeting that further demonstrate the potential of NVC-422 and our Aganocide class of compounds to effectively treat chronic and common fungal skin infections," said Dr. Ron Najafi, chairman and chief executive officer. "Data from the Center for Medical Mycology at Case Western Reserve University Hospitals confirm how our novel, anti-infective agent in an animal model is highly effective not only on the skin surface, but also showed potent ability to kill subcutaneous organisms by route of the hair follicles."

Following are the details on the poster presentation.

    Saturday, March 7
    Poster Title: "Efficacy of NVC 422 in the Topical Treatment of
    Dermatophytosis in a Guinea Pig Model"
    Professor Mahmoud Ghannoum et al
    Time: 9:20 a.m. Pacific Time
    Moscone Center North, Hall E, Abstract #2405

About NVC-422

NVC-422 is the lead molecule in NovaBay's Aganocide class of compounds. NVC-422 is a non-antibiotic, stable analog of an anti-infective molecule produced by white blood cells. NovaBay b
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
2. NovaBay announces third quarter 2007 financial results
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
6. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
10. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
11. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2015)... World Patent Marketing, a vertically integrated ... Little Party Table, a party invention that gives people ... suit their party needs. , "Worldwide indoor and outdoor ... past year. Party Supply Rentals alone are a ... CEO and Creative Director of World Patent Marketing ...
(Date:5/25/2015)... Iowa City, Iowa (PRWEB) May 25, 2015 ... Engineering Excellence awards for design of the ... in Iowa City, Iowa.    The project received a National Recognition ... and an Honor Award from ACEC – Iowa. ... outstanding engineering achievements. , The $50.2 million expansion is ...
(Date:5/25/2015)... Tunstall Americas announces major investment in new technology ... to its Medical Answering Service customers. Through a ... Tunstall now provides a seamless transition between a health ... ensure superior patient satisfaction. , Tunstall is ... million in expanded facilities and the latest telecommunication software ...
(Date:5/24/2015)... Clarkston, Metamora, Michigan (PRWEB) May 24, 2015 ... patients for concerns about hair loss. Although it is ... clear that there are environmental factors such as metabolism, ... can contribute. Since they offer a comprehensive approach to ... peri and post-menopausal woman, they can help patients find ...
(Date:5/24/2015)... York, New York (PRWEB) May 24, 2015 ... testosterone treatment lawsuits ( http://www.testosteronelawsuithub.com/ ) has scheduled ... the progress of the multidistrict litigation. According to ... Northern District of Illinois, the Conference will be ... (In re: Testosterone Replacement Therapy Product Liability Litigation ...
Breaking Medicine News(10 mins):Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 2Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 3Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Women's Excellence Now Treats Menopausal Hair Loss 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Look Ahead to June Conference in Federal Multidistrict Litigation 3
... health insurance providers can motivate and sustain member participation in wellness ... ... Louis, MO (PRWEB) November 6, 2008 -- As a strategic partner ... new whitepaper for health insurance companies that need to improve wellness ...
... Long-Lasting Results and Physician Expertise Most Important, ... A new study,conducted by the American Society ... business of sanofi-aventis U.S. LLC, reveals the,influencers ... medical,anti-aging treatments. The study surveyed women ages ...
... 6 Continuing its efforts to,educate, inform, and ... a,not-for-profit patient-focused organization, is hosting its 25-minute live,call-in ... on,Monday, November 10, 2008 at 6:00 PM on ... frank discussion with Joy Loverde, a,nationally known expert ...
... and Healthier for People With,Diabetes and Their Caregivers, ... a time,for love, laughter, and family, usually accompanied by ... temptations may leave some,of the nearly 24 million people ... Last holiday season, dLife helped over 100,000 online,visitors survive ...
... Corporation,(Nasdaq: RGEN ) today reported results for the ... Total revenue for the quarter was,$5,090,000 compared to total ... 2008 ended September 30, 2007. Total revenue was comprised,of ... of Protein A revenue, for the second quarter of ...
... Corporation,(Nasdaq: RGEN ) announced today that the ... evaluate the use of RG2417, an oral formulation ... 2b study is a,multi-center, randomized, double-blind, placebo-controlled clinical ... will receive,either RG2417 or placebo twice daily for ...
Cached Medicine News:Health News:Health and Wellness Incentives 2Health News:New Study Reveals What Women Want When Considering Cosmetic Procedures 2Health News:Health Caring for the Elderly 2Health News:Back By Popular Demand - dLife Holiday Helpline 2Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 2Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 3Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 4Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 5Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 6Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 7Health News:Repligen Reports Second Quarter Fiscal Year 2009 Financial Results 8Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 2Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 3Health News:Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder 4
(Date:5/22/2015)... The Assistance Fund announces the addition of ... assistance for copay to individuals diagnosed with Melanoma. ... of the Melanoma Copay Assistance Program to our portfolio ... director. "With each additional program we are closer to ... no one is denied access to medications due to ...
(Date:5/22/2015)... NEW YORK , May 22, 2015 /PRNewswire/ ... approval of Zarxio (filgrastim-sndz) -- the first biosimilar ... -- points toward growth in the ... Information. The mainstream CMO industry is geared to ... infrastructure to produce major biopharmaceutical products. The healthcare ...
(Date:5/22/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ) has announced ... Application Dossiers for Oversea Medical device registration and ... to their offering. The Chinese medical ... the most growth potentiality, which is attracting more ... to penetrate such market. It is estimated that ...
Breaking Medicine Technology:The Assistance Fund Adds Melanoma Assistance Program 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3
... Corporation (Nasdaq: DNDN ) today announced that ... Phase 1 clinical trial of D3263 in patients with ... drug candidate designed to target TRPM8 (a transmembrane cation ... The trial is an open-label, dose-escalation study evaluating ...
... strategies for personalized approach to cancer treatmentSEATTLE, April ... subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and ... which utilized RNA interference (RNAi) and bioinformatics to ... that enhance the anti-tumor response to the experimental ...
Cached Medicine Technology:Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer 2Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 2Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 3Genes Identified That Enhance Tumor Cell Sensitivity to CTI's Cancer Drug Brostallicin 4
Integrate RFID and bar code technology with the new DR1000 Dual RFID/Bar Code Reader by Precision Dynamics Corporation (PDC). It provides an easy migration from bar codes to RFID tags for healthcare ...
... only task-critical information to the operator ... Up to 14 additional computers can ... the facility using a dedicated local ... and administrators can all access the ...
... VerdaSee Patient Bracelet-ID™ provides a solution ... personnel to elopement or unauthorized movement ... issues are a key concern. Certain ... care, Alzheimer's victims, patients with highly ...
... a small radio transmitter combines state-of-the-art ... design. The tag incorporates a tamper ... as the tag is attached to ... electronic Heartbeat® signal every 10 seconds ...
Medicine Products: